Professor David Celermajer’s work has focussed on early heart disease in children and young adults at risk of atherosclerosis. His research led to the identification of pre-symptomatic arterial damage and the invention of non-invasive screening for heart disease in young adults.
He was also instrumental in discovering the link between passive smoking and cell damage in the hearts of adolescents and young adults. His investigation into the therapy ‘clozapine’ proved the association between the drug and potentially fatal myocarditis and cardiomyopathy in physically healthy young adults with schizophrenia.
The Scandrett Professor of Cardiology at the University of Sydney, Celermajer is also Director of Echocardiography and Cardiologist at the Royal Prince Alfred Hospital, Clinical Director at the Heart Research Institute, Sydney, and chair of the Research Committee of the National Heart Foundation.
He is a recipient of the Commonwealth Health Minister's Award for Excellence in Health and Medical Research and a Fellow of the Australian Academy of Science.